Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Deferred Revenue (2018 - 2023)

Historic Current Deferred Revenue for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Q2 2023 value amounting to $597000.0.

  • Rocket Pharmaceuticals' Current Deferred Revenue changed 0.0% to $597000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $597000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $597000.0 for FY2022, which is 0.0% changed from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Current Deferred Revenue of $597000.0 as of Q2 2023, which was down 0.0% from $597000.0 recorded in Q1 2023.
  • In the past 5 years, Rocket Pharmaceuticals' Current Deferred Revenue ranged from a high of $597000.0 in Q1 2021 and a low of $541000.0 during Q1 2019
  • In the last 5 years, Rocket Pharmaceuticals' Current Deferred Revenue had a median value of $597000.0 in 2021 and averaged $583000.0.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Current Deferred Revenue soared by 545.81% in 2019, and later changed by 0.0% in 2022.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Current Deferred Revenue stood at $562000.0 in 2019, then increased by 4.98% to $590000.0 in 2020, then rose by 1.19% to $597000.0 in 2021, then changed by 0.0% to $597000.0 in 2022, then changed by 0.0% to $597000.0 in 2023.
  • Its Current Deferred Revenue was $597000.0 in Q2 2023, compared to $597000.0 in Q1 2023 and $597000.0 in Q4 2022.